Steven Pieper Sells 5,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00. Following the completion of the sale, the insider owned 1,356,053 shares of the company’s stock, valued at $11,526,450.50. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $8.58 on Thursday. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -78.00 and a beta of 0.70. The company has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $6.96. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. As a group, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on XERS. Barclays raised their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $115,042,000. Vanguard Group Inc. lifted its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares during the period. Geode Capital Management LLC boosted its position in shares of Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after purchasing an additional 135,815 shares in the last quarter. State Street Corp grew its position in Xeris Biopharma by 10.1% during the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after buying an additional 378,595 shares during the period. Finally, Qube Research & Technologies Ltd increased its holdings in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.